Published on 5 Apr 2024 on Zacks via Yahoo Finance
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
AngioDynamics, Inc. ANGO reported an adjusted loss per share of 16 cents for third-quarter fiscal 2024, wider than the year-ago loss of 3 cents per share and the Zacks Consensus Estimate of a loss of 14 cents per share.
On a pro-forma basis (excluding Dialysis and BioSentry businesses, the divested PICC and Midline product portfolios and the discontinued Uniblate, Starburst and Syntrax products), adjusted loss per share in third-quarter fiscal 2024 was also 16 cents, wider than the adjusted loss per share of 14 cents in the year-ago period.
GAAP loss per share was $4.73, wider than the year-ago period’s loss per share of 24 cents.